Matches in Nanopublications for { ?s ?p "[Activating mutations in the juxtamembrane domain (FLT3-length mutations, FLT3-LM) and in the protein tyrosine kinase domain (TKD) of FLT3 (FLT3-TKD) represent the most frequent genetic alterations in acute myeloid leukemia (AML) and define a molecular target for therapeutic interventions by protein tyrosine kinase (PTK) inhibitors.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 8 of
8
with 100 items per page.
- NP550784.RACjDySOtetOdICgJuaQU5fTNgnhAJq13Jo8vR_jcEu1I130_assertion description "[Activating mutations in the juxtamembrane domain (FLT3-length mutations, FLT3-LM) and in the protein tyrosine kinase domain (TKD) of FLT3 (FLT3-TKD) represent the most frequent genetic alterations in acute myeloid leukemia (AML) and define a molecular target for therapeutic interventions by protein tyrosine kinase (PTK) inhibitors.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP550784.RACjDySOtetOdICgJuaQU5fTNgnhAJq13Jo8vR_jcEu1I130_provenance.
- NP699945.RAT7-pU3MElWBCv66gsxu1N91jKWPYyr0q0WQn2WhKr1Q130_assertion description "[Activating mutations in the juxtamembrane domain (FLT3-length mutations, FLT3-LM) and in the protein tyrosine kinase domain (TKD) of FLT3 (FLT3-TKD) represent the most frequent genetic alterations in acute myeloid leukemia (AML) and define a molecular target for therapeutic interventions by protein tyrosine kinase (PTK) inhibitors.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP699945.RAT7-pU3MElWBCv66gsxu1N91jKWPYyr0q0WQn2WhKr1Q130_provenance.
- assertion description "[Activating mutations in the juxtamembrane domain (FLT3-length mutations, FLT3-LM) and in the protein tyrosine kinase domain (TKD) of FLT3 (FLT3-TKD) represent the most frequent genetic alterations in acute myeloid leukemia (AML) and define a molecular target for therapeutic interventions by protein tyrosine kinase (PTK) inhibitors.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[Activating mutations in the juxtamembrane domain (FLT3-length mutations, FLT3-LM) and in the protein tyrosine kinase domain (TKD) of FLT3 (FLT3-TKD) represent the most frequent genetic alterations in acute myeloid leukemia (AML) and define a molecular target for therapeutic interventions by protein tyrosine kinase (PTK) inhibitors.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP419689.RASTUjdrX1ufiKZlm2kxrA-t4JBN5EIE1fgMQfTRTk3Mk130_assertion description "[Activating mutations in the juxtamembrane domain (FLT3-length mutations, FLT3-LM) and in the protein tyrosine kinase domain (TKD) of FLT3 (FLT3-TKD) represent the most frequent genetic alterations in acute myeloid leukemia (AML) and define a molecular target for therapeutic interventions by protein tyrosine kinase (PTK) inhibitors.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP419689.RASTUjdrX1ufiKZlm2kxrA-t4JBN5EIE1fgMQfTRTk3Mk130_provenance.
- NP419694.RAWcBtIbaQRMDtT3zRve_05xpbKQTl-QuGbN2tjv3Vr-M130_assertion description "[Activating mutations in the juxtamembrane domain (FLT3-length mutations, FLT3-LM) and in the protein tyrosine kinase domain (TKD) of FLT3 (FLT3-TKD) represent the most frequent genetic alterations in acute myeloid leukemia (AML) and define a molecular target for therapeutic interventions by protein tyrosine kinase (PTK) inhibitors.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP419694.RAWcBtIbaQRMDtT3zRve_05xpbKQTl-QuGbN2tjv3Vr-M130_provenance.
- NP376138.RAzAAmMikU-k8feLh4dCkoIQP-UcUl2zDrOuCuiuFmNtg130_assertion description "[Activating mutations in the juxtamembrane domain (FLT3-length mutations, FLT3-LM) and in the protein tyrosine kinase domain (TKD) of FLT3 (FLT3-TKD) represent the most frequent genetic alterations in acute myeloid leukemia (AML) and define a molecular target for therapeutic interventions by protein tyrosine kinase (PTK) inhibitors.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP376138.RAzAAmMikU-k8feLh4dCkoIQP-UcUl2zDrOuCuiuFmNtg130_provenance.
- NP402047.RAPzWwSFvqB0-OL632q0GmJ2QJuJ1jH7WfCUwJyH47jL8130_assertion description "[Activating mutations in the juxtamembrane domain (FLT3-length mutations, FLT3-LM) and in the protein tyrosine kinase domain (TKD) of FLT3 (FLT3-TKD) represent the most frequent genetic alterations in acute myeloid leukemia (AML) and define a molecular target for therapeutic interventions by protein tyrosine kinase (PTK) inhibitors.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP402047.RAPzWwSFvqB0-OL632q0GmJ2QJuJ1jH7WfCUwJyH47jL8130_provenance.